School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Institute of traditional Chinese medicine, Beijing 102488, China.
2 Maternal and women's health department, Shanghai Center for Women and Children's Health, Shanghai 200062, China.
J Tradit Chin Med. 2023 Apr;43(2):239-251. doi: 10.19852/j.cnki.jtcm.20221226.001.
To create the hierarchical model for the comparison of efficacy of different ATs for schizophrenia.
PubMed, Web of Science, Embase, The Cochrane Library, ClinicalTrials, China National Knowledge Infrastructure Database, China Science and Technology Journal Database, Wanfang Database, and SinoMed were searched using a specified search strategy to identify relevant studies up to December 2021. The data were extracted independently by two reviewers. The quality of included trials was evaluated based on the guidelines of "Cochrane Handbook for Systematic Reviews of Interventions". Bayesian network meta-analysis was conducted by statistical analysis software Addis 1.16.6 and Stata 15.1.
In total, 60 randomized controlled trials covering 4810 patients were enrolled. The network meta-analysis result showed that Body Acupuncture (BA), BA + Electro-acupuncture (EA), Scalp Acupuncture (SA) + EA, Auricular Acupuncture (AA), Low-dose medication and Acupuncture (LA), Acupoint Injection (AI), and Acupoint Catgut Embedding (ACE), when combined with Western Medications (WM), demonstrated a better clinical effect at improving the symptoms of schizophrenia, compared to WM alone. Results of rank probability showed that BA, when combined with WM, was the most optimal AT for schizophrenia at decreasing three aspects of PANSS scale score.
Acupuncture-related therapies help improve the symptoms of schizophrenia, and BA combined with WM may be a better therapy for schizophrenia. This study has been registered on the "PROSPERO" website, and the registration number is CRD42021227403.
构建抗精神分裂症药物疗效比较的层次模型。
计算机检索 PubMed、Web of Science、Embase、The Cochrane Library、ClinicalTrials、中国知网、中国科技期刊数据库、万方数据库和中国生物医学文献数据库，搜集比较不同抗精神分裂症药物疗效的相关研究，检索时限均为建库至 2021 年 12 月。由 2 位评价员独立筛选文献、提取资料并评价纳入研究的偏倚风险后，采用 Addis 1.16.6 统计分析软件和 Stata 15.1 进行贝叶斯网状 Meta 分析。
共纳入 60 个随机对照试验，包含 4810 例患者。网状 Meta 分析结果显示，体针（BA）、BA 联合电针（EA）、头针（SA）联合 EA、耳针（AA）、低剂量药物联合针刺（LA）、穴位注射（AI）和穴位埋线（ACE）联合西药（WM）较 WM 单独使用在改善精神分裂症患者症状方面均具有更好的临床疗效。排序概率结果显示，BA 联合 WM 是降低 PANSS 量表评分 3 个方面最具优势的针刺相关疗法。
针刺相关疗法有助于改善精神分裂症患者的症状，BA 联合 WM 可能是治疗精神分裂症的一种更好的选择。本研究已在 PROSPERO 注册，注册号为 CRD42021227403。
